Iovance Biotherapeutics (IOVA) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Iovance Biotherapeutics NASDAQ: IOVA is preparing to seek a lung cancer indication for its cell therapy AMTAGVI in 2027 while expanding its melanoma treatment network and advancing studies in earlier-stage melanoma and r…

Iovance's Amtagvi had its best quarter, at $101.60 million, up 77%, and operating cash burn nearly stopped at -$4.47 million. Proleukin did half of the sequential jump. The lung update sank the stock 47.60% from October …

PHILADELPHIA, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymph…

NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA). Such investors are advised to contact Dan…

Iovance beat Q3 2026 earnings and revenue estimates as Amtagvi sales top $100 million, margins improve and R&D costs decline.…

Iovance Biotherapeutics, Inc., delivered strong Q3 results, with revenues up ~80% YoY and gross margin rising to 60%. IOVA reaffirmed 2026 guidance of $410–$420M revenue, and maintains a robust cash position ($376M) expe…

Iovance Biotherapeutics, Inc. fell 46% after my downgrade to Hold in September, reflecting over-optimism in valuation. AMTAGVI's (lifileucel) melanoma launch gained momentum, but the NSCLC opportunity appeared overestima…

Iovance reaffirms its 2026 revenue outlook as Q3 sales jump 80%, fueled by Amtagvi adoption, improving margins and progress in its cancer pipeline.…

Iovance Biotherapeutics, Inc. ( IOVA ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Jen Saunders Frederick Vogt - Interim CEO, President, General Counsel, Corporate Secretary & Director Corleen…

Iovance Biotherapeutics NASDAQ: IOVA reported record third-quarter revenue of approximately $122 million, up 80% from a year earlier, as sales of its melanoma treatment AMTAGVI surpassed $100 million in a quarter for the…

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.25 per share a year ago.…

Total Revenue Increased ~80% and U.S. Amtagvi Revenue Increased ~77% Year-over-Year, and Gross Margin Increased to ~60% 24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous Metastatic Non-Small-Cell Lung…

IOVA is poised for a Q3 earnings beat as Amtagvi sales drive revenue, Proleukin adds growth and pipeline progress draws investor attention.…

Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer Transcript…

Iovance Biotherapeutics NASDAQ: IOVA reported updated data from its registrational IOV-LUN-202 trial of lifileucel in previously treated, non-squamous metastatic non-small cell lung cancer, outlining plans for a suppleme…

Iovance Biotherapeutics (IOVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous mNSCLC, Consistent with Previously Reported Results IOV-LUN-202 Cohorts 1 and 2 Are Completing Enrollment and Support a Planned Supplemental Biologics …

Live Webcast at 8:30 a.m. ET on Thursday, October 29, 2026 PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developin…

IOVA, MEI and PRMRF made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 27th, 2026.…

NTSK, PRMRF, IOVA, CAPL and MEI have been added to the Zacks Rank #1 (Strong Buy) List on October 27th, 2026.…

PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymph…

50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 Unprecedented Efficacy in Both Refractory Undifferentiated …

62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 Analysis Median Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-up Oral Presentation at the Eur…

Iovance Advances TIL Cell Therapy into a New Chapter in Solid Tumor Treatment Two Oral Presentations to Showcase Deep, Durable Responses with TIL Cell Therapy in Frontline Melanoma and Previously Treated Soft Tissue Sarc…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

